---
title: "J&#038;J in Talks to Buy Eye-Drug Maker Ollin for Up to $3.4 Billion"
url: https://www.herejacksonville.com/2026/11/16/johnson-johnson-ollin-biosciences-3-4-billion-talks/
date: 2026-11-16T05:55:22-05:00
modified: 2026-11-16T05:55:22-05:00
author: "Merger Monday"
categories: ["Business", "National"]
site: "HERE Jacksonville"
attribution: "HERE Jacksonville"
---

# J&#038;J in Talks to Buy Eye-Drug Maker Ollin for Up to $3.4 Billion

*Source: [HERE Jacksonville](https://www.herejacksonville.com/2026/11/16/johnson-johnson-ollin-biosciences-3-4-billion-talks/) — November 16, 2026 by Merger Monday*

Johnson & Johnson announced Monday that it has entered into a definitive agreement to acquire Ollin Biosciences, a privately held developer of eye-disease drugs, for $2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments of up to about $1.125 billion. The purchase would push the health-care giant deeper into retinal medicine.

The company said the transaction is expected to close before the end of 2026, subject to regulatory approvals and customary closing conditions. Johnson & Johnson also said it would enter a separate development funding agreement with Blackstone Life Sciences, contingent on the acquisition closing, under which Blackstone would pay a total of $750 million over multiple years to fund late-stage work on Ollin’s lead drug.

## Going after the retina

Ollin, backed by ARCH Venture Partners and Mubadala Capital, is developing OLN324, an antibody designed to block two proteins, VEGF and Ang2, that drive abnormal blood vessel growth and leakage in the eye. The company has said it planned to begin late-stage trials in diabetic macular edema and wet age-related macular degeneration in the second half of 2026. It raised $330 million in June to pay for those studies.

Its pipeline also includes OLN102, a bispecific antibody targeting two receptors involved in thyroid eye disease and Graves disease.

The retinal market is dominated by injected drugs such as Regeneron and Bayer products and Roche, whose Vabysmo already hits the same two targets. J&J sells contact lenses and surgical vision equipment but has little presence in prescription retinal drugs, so a deal would give it a late-stage entry rather than starting from scratch.

## A record year for biotech buyouts

The agreement comes in a record year for biotech takeovers. Investment bank Stifel has counted 46 acquisitions of biotech companies valued at more than $1 billion so far this year, above the previous annual high of 35. Recent examples include AstraZeneca and its roughly $10 billion offer for Rhythm Pharmaceuticals and argenx agreeing to buy Unnatural Products for up to $1.15 billion.

The structure, with a large slice of value held back for milestones, has become standard for drugs that have not yet finished pivotal trials. It lets the buyer cap what it pays if the science disappoints while giving venture backers a return on a company that has not had to test the public markets.
